Abstract
Bisphosphonates have been safely used to treat osteoporosis, effectively reducing fracture risk after 3 to 5 years of treatment. Recent concerns about long-term safety coupled with posttreatment fracture risk reduction have increased support for drug holidays. The decision to start low-risk patients on drug holidays must be based on current fracture risk assessment.
MeSH terms
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / therapeutic use*
-
Diphosphonates / adverse effects
-
Diphosphonates / therapeutic use*
-
Drug Administration Schedule
-
Duration of Therapy
-
Fractures, Bone / prevention & control
-
Humans
-
Osteoporosis / drug therapy
-
Risk Assessment
-
Withholding Treatment*
Substances
-
Bone Density Conservation Agents
-
Diphosphonates